LumiCyte, which doesn't seem to have any poster presentations at AACR, is instead hyping its booth:
>>(BW HealthWire)--
LumiCyte Will Display Their Revolutionary SELDI-Based Biotechnology
Services at Booth #714 at the AACR 93rd Annual Meeting
in San Francisco on April 7-10
WHO LumiCyte, Inc. -- a biotechnology company that enables the
early diagnosis of cancer and drives the evolution of drug
development.
Dr. Bill Hutchens -- Founder and CEO of LumiCyte and inventor
of the SELDI proteomics technology.
WHAT As an exhibitor at the AACR 93rd Annual Meeting, at the
Moscone Convention Center in San Francisco, Calif., LumiCyte
will showcase its SELDI-based biotechnology services and
announce that it has achieved an exciting new level of
protein-mapping capabilities as benchmarked by today's most
sophisticated technologies.
LumiCyte generates high-information content protein maps with
unprecedented speed, sensitivity and accuracy. Analysis of
these maps with LumiCyte's proprietary suite of neural network
and pattern recognition software enables:
-- Early detection of disease onset
-- More effective classification of disease
-- More accurate monitoring of disease progression
-- Early indication of patient-specific response to
therapy
LumiCyte's biochip products are low cost, distributable sample
collection and diagnostic devices that are being used in
support of clinical trials.
WHEN: April 7-10, 2002
WHERE: Moscone Convention Center, Booth 714, San Francisco, Calif.
INTERVIEWS: Dr. Bill Hutchens will be available on April 8-10 by
appointment only. Hutchens and the team at LumiCyte
pioneered the development of advanced biochips and
informatics technologies to generate comprehensive
human serum protein maps. To schedule a meeting,
contact either:
CONTACT: J.P. Carr Louise Bono
Sterling Hager LumiCyte, Inc.
415/591-8402 510/413-9224
jp@sterlinghager.com lbono@lumicyte.com
LumiCyte: The advanced, proprietary biotechnology services offered exclusively by Fremont, Calif.-based LumiCyte, Inc. allow pharmaceutical and biotechnology companies to optimize drug development, and enable physicians to offer more individualized and accurate care to their patients. www.lumicyte.com
LumiCyte combines THREE core technologies to offer contract services that remove the inefficiencies found today in the pharmaceutical and biotechnology industries' multi-billion dollar drug development process:
1. Advanced SELDI Biochips that feature the most sensitive,
accurate and comprehensive protein-mapping capabilities
available.
2. Patented and proprietary Data Analysis Software that was
developed to identify patterns within the high-resolution
protein topographical maps produced by the LumiCyte Biochip.
3. The BioPhore Knowledgebase(TM), an open-architecture
information platform that integrates our disease-specific
protein information with other genomics, proteomics and
clinical information. The BioPhore Knowledgebase currently
holds records for over 2200 human serum proteins with 180
descriptors each.<<
Cheers, Tuck |
